Russell Investments Group
GLUE icon

Russell Investments Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Russell Investments Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$938K Buy
38,774
+31,386
+425% +$593K ﹤0.01% 2493
2026
Q1 		$122K Buy
7,388
+3,070
+71% +$58.7K ﹤0.01% 3024
2025
Q4 		$67.7K Hold
4,318
– – ﹤0.01% 3187
2025
Q3 		$32K Buy
+4,318
New +$22.9K ﹤0.01% 3442
2024
Q3 		– Sell
-2,631
Closed -$9.84K – 3733
2024
Q2 		$9.84K Buy
+2,631
New +$13.4K ﹤0.01% 3079
2023
Q3 		– Sell
-1,431
Closed -$9.8K – 3563
2023
Q2 		$9.8K Hold
1,431
– – ﹤0.01% 2970
2023
Q1 		$11.1K Hold
1,431
– – ﹤0.01% 2869
2022
Q4 		$10.9K Hold
1,431
– – ﹤0.01% 2840
2022
Q3 		$11K Buy
+1,431
New +$13.1K ﹤0.01% 2855

Other funds holding GLUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Russell Investments Group's GLUE Position: Q2 2026 in Review

Russell Investments Group increased its Monte Rosa Therapeutics (GLUE) stake by 425% in Q2 2026, buying an estimated $593K and bringing the position to 38,774 shares worth $938K. The position accounts for ﹤0.01% of the portfolio, ranked #2493.

Russell Investments Group first reported a position in GLUE in Q3 2022 and has held it in 9 quarters since. 58 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Russell Investments Group held 38,774 shares of Monte Rosa Therapeutics worth $938K as of Q2 2026.
  • Russell Investments Group bought 31,386 Monte Rosa Therapeutics shares in Q2 2026, an estimated $593K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2493 holding.
  • Russell Investments Group first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • 58 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.